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Abstract
Background: Environmental lead exposure among adults may increase blood pressure and elevate the risk of
hypertension. The availability of data on blood lead levels (BLL) in adult Brazilian population is scarce and
population-based studies are important for screening the population exposure and also to evaluate associations
with adverse health effects. The goal of this study was to examine the association of BLL with blood pressure and
hypertension in a population-based study in a city in Southern Brazil.
Methods: A total of 948 adults, aged 40 years or older, were randomly selected. Information on socioeconomic,
dietary, lifestyle and occupational background was obtained by orally administered household interviews. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP) were measured according to the guidelines VI Brazilian
Guidelines on Hypertension. BLL were measured by inductively coupled plasma mass spectrometry technique.
Multiple linear and logistic regression models were performed to evaluate associations of BLL with SBP and DBP,
and with the chance of hypertension and of elevated SBP and DBP.
Results: The geometric mean of BLL was 1.97 μg/dL (95%CI:1.90-2.04 μg/dL). After multivariable adjustment,
participants in the quartile 4 of blood lead presented 0.06 mm/Hg (95%CI, 0.04-0.09) average difference in DBP
comparing with those in quartile 1. Participants in the 90th percentile of blood lead distribution had 0.07 mmHg
(95% CI, 0.03 to 0.11) higher DBP compared with those participants in the 10th percentile of blood lead. The
adjusted OR for hypertension was 2.54 (95% CI, 1.17-5.53), comparing the highest to the lowest blood lead
quartiles. Compared with participants in the 10th percentile of blood lead, participants in the 90th percentile
presented higher OR for hypertension (OR: 2.77; 95% CI, 1.41 to 5.46).
Conclusion: At low concentrations, BLL were positively associated with DBP and with the odds for hypertension in
adults aged 40 or older. It is important to enforce lead exposure monitoring and the enactment of regulatory laws
to prevent lead contamination in urban settings.
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Background
Chronic lead exposure and accumulation in the body
can lead to progressive health effects. Among these ef-
fects, increased blood pressure, which is associated with
the onset of cardiovascular diseases, has been linked to
lead exposure. The hypertensive effects of lead have
been widely reported in workers exposed to high levels
of the metal and by experimental studies in which ani-
mals were exposed to long-term high doses of lead.
Under occupational conditions, the development of
hypertension has been implicated as a possible conse-
quence of the nephropathy caused by lead exposure.
Studies have concluded that lead exposure is a risk fac-
tor for raised blood pressure and hypertension even in
the general population [1–4].
Publications of NHANES (National Health and Nutri-
tion Examination Survey) data have reported a decline
of environmental lead exposure in the United States and
consequent lower blood lead concentrations in the
American population. While early studies had noticed
positive and significant associations between blood lead
and blood pressure, more recent studies have questioned
the consistency of this association in view of the lower
blood lead concentrations observed in the last published
data [5–10]. A meta-analysis of the epidemiological
studies available from 1980 to 2001 reported that a 2-
fold increase in blood lead concentration was associated
with a 1.0 mm Hg increase in systolic blood pressure
and a 0.6 mm Hg increase in diastolic blood pressure
[11]. Recent data have suggested that the effect sizes in
the associations of blood pressure and blood lead (mean
of 1.51 μg/dL) are small and inconsistent [6], or that a
modest association was found [12].
Hypertension is a major risk factor for cardiovascular
disease, which remains the leading cause of death in
Brazil, representing about 13% of disability adjusted life
years (DALYs) [13, 14]. Globally, raised blood pressure is
the leading noncommunicable diseases risk factor, to
which 13% of deaths are attributed. The prevalence of
raised blood pressure in adults aged 25 years or older
was about 40% in 2008, and is generally more prevalent
in men than in women (39% for men and 32% for
women) [15]. In Brazil, the prevalence is similar to other
countries, occurring in 35.8% of men and 30% of women
with general estimate of over 30% in both sexes, and
prevalence increases with age (≥60 years old) [16–18].
In view of the low blood lead concentrations found in
our study (1.97 μg/dL) and the divergent results pub-
lished on literature, we aimed to examine the relation-
ship of blood lead with blood pressure and hypertension
in a population-based sample of Brazilian adults living in
southern Brazil. Besides, few studies have evaluated the
scientific evidence on blood lead and adverse health ef-
fects on the Brazilian general population. Our study
focused on adults aged 40 years or older who, as com-
pared to younger persons have increased risk factors for
cardiovascular diseases, and also were probably exposed
to higher concentrations of lead before 1985, when the
withdrawal of tetraethyl lead in automotive gasoline oc-
curred in Brazil [19].
Methods
The study population included adults aged 40 years or
older residents in an urban area in southern Brazil. In
2011, participants were randomly selected and took part
in a household interview, anthropometric measurements
and laboratory tests. Complete information of the study
design and sampling has already been published [20, 21].
The accomplished study had a census based design,
using data from the Population Count 2007, when the
city of Cambé had a total of 92,888 people, of whom
30,710 (33.1%) were aged 40 or older (46% men and 54%
women) [22]. All census tracts in the urban region were
included in the study and the number of subjects to be
interviewed in each tract was calculated proportionally
to the amount of men and women aged 40 or over, and
a quota of individuals, according to gender and age
range, with five-year intervals was defined.
A total of 1180 (88.3%) of the selected persons com-
pleted the interview and 959 (81.3%) performed blood
collection [20]. For the present analysis, we used data
from 948 subjects who participated in the interviews,
who had performed blood tests and had blood pressure
measurements. Eleven participants missing information
on blood pressure were excluded from this analysis.
The measurements were taken according to the VI
Brazilian Guidelines on Hypertension, organized by the
Brazilian Hypertension Society [23], by using the digital
equipment Omron HEM 742. Measurements were ob-
tained at both arms, and in case of difference, we used
data from the arm with the highest value as a reference
for subsequent measures. At least three measurements
were performed with one minute interval between them,
with the participant in a sitting position. The mean of
the last two blood pressure measurements was consid-
ered the most accurate blood pressure. Participants were
considered as hypertensive if any of the following criteria
were present: a systolic blood pressure of 140 mm Hg or
higher, a diastolic blood pressure of 90 mm Hg or
higher, or self-reported use of antihypertensive medica-
tion. Systolic and diastolic blood pressures were also ex-
amined as separate dichotomous variables considering
the same cutoff values.
Whole blood samples of approximately 5 ml were ob-
tained by venipuncture after skin disinfection with alco-
hol 70%, collected in heparinized metal-free containers
and kept under refrigeration until sent to the laboratory.
Once in the laboratory, the samples were stored at
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−50 °C until being processed. Blood lead concentration
was measured in duplicate by inductively coupled
plasma mass spectrometry (ICP-MS) in the Adolfo Lutz
Institute, São Paulo. To evaluate the accuracy of the re-
sults, the standard reference material Toxic Metals in
Bovine Blood, from National Institute of Standards and
Technology (NIST 966 levels 1 and 2) was used. The ob-
tained results were: 1,315 ± 0.05 μg/100 ml (level 1) and
24.95 ± 0.07 μg/100 ml (level 2), showing good agree-
ment with the certified values, 1,459 ± 0.013 μg/100 ml
and 25.27 ± 0.22 μg/100 ml, respectively. The within-
and-between batch precision were 4% and 6% for
1,459 μg/100 ml and 1% and 3% for 25.27 μg/100 ml, re-
spectively. The detection and the quantification limits
were obtained by 10 consecutive measurements of a
blood sample with low lead level. These limits were cal-
culated as three times and 10 times the standard devi-
ation of those measurements. The results were 0.0029
and 0.0096 μg/100 ml for detection limit and quantifica-
tion limit, respectively. Considering the dilution factor
used for the sample preparation, the final limit of quan-
tification was 0.20 μg/100 ml. Only one sample was
below the limit of quantification and in this case the
value of 0.20 μg/100 ml was assigned. All the analyses
were performed in an ISO Class 7 cleanroom facility.
Information on sex, age (years), race, education, in-
come class, occupation, smoking and alcohol consump-
tion was obtained from each subject by the orally
administered household interviews [21]. Race was cate-
gorized as white and non-white according to self-
reported answers. Education was based on the self-
reported number of years of education completed, (0–3,
4–7, 8–11 and 12 or more years of study). Income class
was defined according to the Economic Classification
Criterion Brazil (Critério de Classificação Econômica
Brasil - CCEB) from the Brazilian Association of Re-
search Companies [24]. This tool estimates the purchas-
ing power and economic status of respondents, divided
into classes A through E. For this study, this variable
was categorized as A/B classes (corresponding to the
higher income levels), C (medium income level) and D/
E classes (related to the lower income levels). Occupa-
tion was queried in terms of potential lead exposure,
based on self-reported current or former employment in
any of the following of the lead using industries as de-
fined by CNAE (National Classification of Economic Ac-
tivities). These included: manufacture and recycling of
batteries, secondary smelters, alloy production, electro-
plating, welding, PVC and other plastic manufacture and
rubber recycling industry. Cigarette smoking was catego-
rized as never, former and current smoker and alcohol
consumption was categorized as either drinking or not
drinking alcoholic beverages. Body mass index (BMI) in-
formation was obtained from the physical examination
and calculated as weight in kilograms divided by the
square of height in meters. Weight was measured with
an electronic scale, with a precision of 0.1 kg and max-
imum capacity of 150 kg. The individuals were weighted
barefoot, standing upright at the center of the scale plat-
form and wearing light clothing. Height was measured
with a portable stadiometer with a precision of 0.1 m
and maximum length of two meters. The participants
stood, barefoot, with their back turned to the vertical
surface of the equipment and head positioned in the
Frankfurt plane, with arms relaxed at the side of the
body, with palms facing the thighs united heels, touching
the vertical part of the stadiometer and medial edges
spaced apart. The movable part of the stadiometer was
elevated until touching the vertex, compressing the hair
[21]. Current antihypertensive medication use was self-
reported and participants were considered as taking
these medications according with the VI Brazilian
Guidelines of Hypertension [23]. The antihypertensive
medications were shown to the interviewer at the mo-
ment of the interview. However, some of these medica-
tions as carvedilol (alpha-beta adrenergic blocker) and
spironolactone (potassium-sparing diuretic), both pre-
scribed for the treatment of congestive heart failure, and
the medication verapamil retard (calcium channel
blocker), used to treat cardiac arrhythmia, were not con-
sidered as current use of antihypertensive medication
[25, 26]. In the case of diuretics use, a non-specific
medication for the treatment of hypertension, the par-
ticipant was considered to have hypertension depending
on the self-reported question. For this, the following
question was asked to the respondent: “Which of the
following diseases have you ever been told by a doctor
or other health professional (doctor, nurse, pharmacist,
etc.) do you have or had?” Total cholesterol, high-
density lipoprotein (HDL), triglycerides and glucose were
performed using automated methodology to Dimension®
RXL biochemical system model. The low-density lipo-
protein (LDL) was calculated using the Friedewald equa-
tion [27].
For statistical analysis we used the software Stata [28]
to perform descriptive and inferential statistical tests.
Means, percentages and standard errors were estimated
to describe the sample characteristics. Blood lead levels
were left skewed and log transformed for analysis. Out-
come variables, systolic and diastolic blood pressures
were, respectively, inverse and log transformed to follow
normal distribution. Multiple linear regression models
were performed to examine associations of blood lead
with systolic and diastolic blood pressures comparing
those participants in quartiles 2 to 4 of blood lead levels
with those in quartile 1. Multiple logistic regression ana-
lysis was used to evaluate the risk of hypertension also
by categorizing blood lead in quartiles. We also
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performed Pearson correlation analysis to verify the cor-
relations between systolic and diastolic blood pressure
with blood lead levels.
Regression models were constructed based on a priori
knowledge and biologic association with blood pressure
(age, sex, antihypertensive medication use and blood
lead log transformed). Other covariates were added to
the model in two separated blocks: Model 1 – sex, age,
race, income, education, antihypertensive medication
and blood lead level; Model 2 – model 1 + total choles-
terol, triglycerides, glycemia, smoking, alcohol consump-
tion and body mass index. A third model was further
adjusted for occupation status. These variables were in-
cluded because they were significantly associated with
blood pressure outcomes in at least one of the models
performed before the inclusion of blood lead, consider-
ing a p < .20. Additionally, we performed regression ana-
lyses with only the subgroup that was not taking
antihypertensive medication to elucidate if we would
find significant changes in results. After running each
model, the distribution of the residuals was tested for
normality. Statistical tests with p value < .05 were con-
sidered statistically significant.
Results
The overall geometric mean of blood lead level was
1.97 μg/dL (95% CI, 1.89–2.04), and the means for the
blood lead quartiles ranged from 0.96 μg/dL to 4.21 μg/
dL in the lowest and higher quartile, respectively. Blood
lead levels were higher in men, in older participants (50
to 59 years old), in non-white, in smokers and drinkers,
and in subjects with normal BMI. Participants currently
or former employed in lead industries had higher blood
lead levels (2.65 μg/dL; 95% CI, 2.31–3.05) than those
not employed (Table 1).
Of the 948 participants in the sample, 519 (54.7%)
were classified as hypertensive, of whom 398 were classi-
fied as hypertensive according to their systolic and/or
diastolic blood pressures, and 121 if they self-reported
current use of antihypertensive medication. A total of
181 subjects had both systolic and diastolic hyperten-
sion, 164 had only systolic hypertension, 53 had diastolic
hypertension. Among the 220 untreated subjects, 73 had
systolic hypertension only, 39 had diastolic hypertension,
and 108 had both systolic and diastolic hypertension. Of
those who reported being treated for hypertension (n =
299), 91 had only systolic hypertension, 14 had diastolic
hypertension, and 73 had both systolic and diastolic
hypertension. Participants with hypertension (systolic
blood pressure ≥140 mm Hg, diastolic blood pressure
≥90 mm Hg, or self-reported use of antihypertensive
medication) had higher blood lead levels (2.04 μg/dL;
95% CI, 1.94–2.15) than those not hypertensive (1.87 μg/
dL; 95% CI, 1.77–1.98) (Tables 1 and 2). The results of
the Pearson correlation analysis for systolic blood pres-
sure and blood lead levels was r = 0.088, p < 0.005, and
for diastolic blood pressure the coefficient was r = 0.112,
p < 0.005.
In unadjusted analysis, participants with elevated sys-
tolic and diastolic blood pressure presented higher blood
lead concentration (2.16 μg/dL; 95% CI, 2.02–2.31) and
(2.31 μg/dL; 95% CI, 2.13–2.51), compared with those
with normal systolic and diastolic blood pressure
(1.86 μg/dL; 95% CI, 1.78–1.95) and (1.86 μg/dL; 95%
CI, 1.79–1.94), respectively. Hypertensive individuals
had increased concentrations of total cholesterol, triglyc-
erides and glycemia than those not hypertensive. Con-
troversially, we observed that participants with higher
levels of HDL had higher blood lead concentrations than
those with decreased HDL (Tables 1 and 2).
In multivariate analysis, there was a weak association
of blood lead with both systolic and diastolic blood pres-
sure. After multivariable adjustment, participants in the
quartile 4 of blood lead presented 0.06 mm/Hg (95% CI,
0.04–0.09) average difference in diastolic blood pressure
comparing with those in quartile 1. For systolic blood
pressure, the average difference was almost insignificant
(Table 3). Participants in the 90th percentile of blood
lead distribution had 0.07 mmHg (95% CI, 0.03 to 0.11)
higher diastolic blood pressure compared with those
participants in the 10th percentile of blood lead. The
geometric mean of blood lead level of participants in the
10th percentile and in the 90th percentile was 0.74 μg/
dL (95% CI, 0.71–0.77) and 6.03 μg/dL (95% CI, 5.52–
6.58), respectively.
The adjusted OR for hypertension comparing the
highest to the lowest blood lead quartiles was 2.54 (95%
CI, 1.17–5.53). Compared with participants in the 10th
percentile of blood lead, participants in the 90th per-
centile presented higher OR for hypertension (OR: 2.77;
95% CI, 1.41 to 5.46) (Table 4).
When we further adjusted for occupational status, the
results did not significantly change and the overall sig-
nificance was maintained.
The results of the multivariate analysis when consider-
ing only the subjects not taking antihypertensive medi-
cation (n = 649) were similar to those results of the
sample including the whole population. Only a minor
centesimal difference was observed for the OR and 95%
CI as shown in Tables 3 and 4.
Discussion
In this study we found a significant association between
small increases in blood lead levels and elevations in sys-
tolic and diastolic blood pressures. The association of
blood lead was +0.06 mm Hg (p < 0.001) for diastolic
blood pressure, while the association for systolic blood
pressure was statistically significant (p < 0.05), with no
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Table 1 Blood lead levels (μg/dL) by participant characteristics
Characteristic n (%) Percentile 50th (median) Interquartile range Min – max values Geometric means (95% CI) p-Valuea
Overall 948 (100) 1.94 1.44 0.46 – 45.62 1.97 (1.90, 2.04)
Sex
Male 421 (44.4) 2.46 1.72 0.65 – 45.62 2.59 (2.46, 2.73) <0.001
Female 527 (55.6) 1.59 0.99 0.46 – 27.91 1.58 (1.51, 1.65)
Age (years)
40 – 49 386 (40.7) 1.83 1.46 0.48 – 27.91 1.84 (1.73, 1.96) 0.001
50 – 59 294 (31.0) 2.09 1.42 0.54 – 21.83 2.13 (2.00, 2.28)
≥ 60 268 (28.3) 1.94 1.36 0.46 – 45.62 1.98 (1.84, 2.12)
Race
White 562 (59.3) 1.87 1.42 0.46 – 45.62 1.88 (1.79, 1.97) 0.084
Non white 386 (40.7) 2.03 1.48 0.49 – 24.49 2.09 (1.97, 2.23)
Education (years)
0 – 3 229 (24.2) 1.99 1.28 0.46 – 10.78 1.94 (1.81, 2.08) 0.055
4 – 7 357 (37.7) 1.94 1.51 0.51 – 45.62 2.00 (1.88, 2.14)
8 – 11 265 (28.1) 1.99 1.64 0.49 – 27.91 2.03 (1.88, 2.20)
12 or more 97 (10.0) 1.74 0.94 0.68 – 8.79 1.72 (1.56, 1.90)
Income classb
A and B 348 (36.8) 1.95 1.44 0.48 – 45.62 1.97 (1.85, 2.11) 0.259
C 514 (54.3) 1.97 1.49 0.46 – 13.03 1.98 (1.88, 2.08)
D and E 85 (8.9) 1.74 1.20 0.51 – 24.49 1.85 (1.61, 2.11)
Occupation
Exposed to lead 114 (12.0) 2.48 2.11 0.7 – 45.62 2.65 (2.31, 3.05) <0.001
Not exposed to lead 834 (88.0) 1.89 1.35 0.46 – 27.91 1.89 (1.82, 1.96)
Smoking
Never 498 (52.5) 1.71 1.10 0.46 – 45.62 1.68 (1.59, 1.76) <0.001
Former 268 (28.3) 2.05 1.57 0.56 – 8.53 2.11 (1.98, 2.25)
Current 182 (19.2) 2.64 2.18 0.87 – 27.91 2.73 (2.50, 2.98)
Alcohol Consumption
Do not drink 584 (61.6) 1.74 1.19 0.46 – 27.91 1.74 (1.67, 1.83) <0.001
Drink 364 (38.4) 2.26 1.72 0.56 – 45.62 2.38 (2.24, 2.53)
Systolic blood pressure
< 140 mm Hg 603 (63.6) 1.88 1.39 0.48 – 27.91 1.86 (1.78, 1.95) <0.001
≥ 140 mm Hg 345 (36.4) 2.07 1.58 0.46 – 45.62 2.16 (2.02, 2.31)
Diastolic blood pressure
< 90 mm Hg 714 (75.3) 1.86 1.35 0.46 – 45.62 1.86 (1.79, 1.94) <0.001
≥ 90 mm Hg 234 (24.7) 2.19 1.73 0.50 – 24.49 2.31 (2.13, 2.51)
Hypertensionc
No 429 (45.3) 1.88 1.46 0.49 – 27.91 1.88 (1.77, 1.98) 0.099
Yes 519 (54.7) 2.00 1.47 0.46 – 45.62 2.04 (1.94, 2.15)
Glycemia (mg/dL)
< 100 499 (52.6) 1.85 1.42 0.49 – 27.91 1.91 (1.81, 2.01) 0.278
≥ 100 449 (47.4) 2.00 1.44 0.46 – 45.62 2.03 (1.92, 2.15)
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difference observed in the 95% CI, showing a modest in-
crease. However, the OR for hypertension was higher in
participants in the quartile 4 of blood lead compared
with those in the quartile 1 (OR = 2.54; 95% CI, 1.17–
5.53). The geometric mean blood lead concentration of
1.97 μg/dl (95% CI, 1.89–2.04) found in the present
study was higher than the concentration of 1.64 μg/dl
reported by Bushnik et al. [12], in a survey at national
level with the Canadian population aged 40 to 79 years
old. These authors reported a significant association be-
tween systolic and diastolic blood pressure and lead con-
centrations for subjects aged 40 to 54 years old and for
men, but not with the odds for hypertension [12].
Prospective studies have suggested that there is suffi-
cient evidence to infer a causal relationship of lead ex-
posure with hypertension, besides the modest strength
Table 1 Blood lead levels (μg/dL) by participant characteristics (Continued)
HDL (mg/dL)
≥ 50 female ≥40 male 483 (50.9) 2.04 1.68 0.49 – 27.91 2.13 (2.02, 2.26) 0.003
< 50 female <40 male 465 (49.1) 1.84 1.19 0.46 – 45.62 1.80 (1.71, 1.89)
LDLd (mg/dL)
< 160 767 (83.5) 1.90 1.42 0.46 – 27.91 1.92 (1.84 – 2.00) 0.574
≥ 160 151 (16.4) 2.01 1.36 0.60 – 12.88 2.07 (1.90 – 2.27)
Total cholesterol (mg/dL)
< 200 452 (47.7) 1.88 1.48 0.49 – 27.91 1.90 (1.80, 2.01) 0.188
≥ 200 496 (52.3) 1.99 1.36 0.46 – 45.62 2.03 (1.92, 2.14)
Triglycerides (mg/dL)
< 150 622 (65.6) 1.89 1.51 0.48 – 27.91 1.94 (1.85, 2.03) 0.296
≥ 150 326 (34.4) 2.01 1.31 0.46 – 45.62 2.02 (1.90, 2.16)
Body Mass Indexe (Kg/m2)
15 - <25 289 (30.8) 1.96 1.74 0.49 – 27.91 2.10 (1.95, 2.26) 0.004
25 - <30 357 (38.1) 2.03 1.40 0.50 – 21.83 2.02 (1.90, 2.14)
≥ 30 291 (31.1) 1.85 1.15 0.46 – 45.62 1.95 (1.37, 2.78)
at-Student and Kruskal-Wallis test. bAccording to ABEP, 2012. Data missing for one participant. cAccording with VI Diretriz Brasileira de Hipertensão. Hypertension
defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or current antihypertensive medication. d30 missing data on this variable
(n = 918). e11 missing data on this variable (n = 937)
Table 2 Participants characteristics by hypertension statusa
Characteristics Hypertension (n = 519) No hypertension (n = 429) All (n = 948) P valueb
Age (years) 57.6 (0.46) 50.9 (0.44) 54.5 (0.34) <0.001
Sex (% male) 42 (0.02) 47 (0.02) 44.5 (0.16) 0.114
Race (% white) 58 (0.02) 61 (0.02) 59 (0.01) 0.375
Education (years of study) 5.62 (0.19) 7.24 (0.21) 6.35 (0.14) <0.001
Income class (% middle income class)c 59 (0.02) 48 (0.02) 54 (0.02) 0.001
Smoking
Former smoker (%) 32 (0.02) 23 (0.02) 28.3 (0.01) 0.001
Current smoker (%) 16 (0.16) 23 (0.02) 19 (0.01)
Alcohol intake (% drinker) 42 (0.02) 36 (0.02) 38.4 (0.01) 0.055
Total cholesterol (mg/dL) 206.8 (1.83) 200.5 (1.80) 203.9 (1.29) 0.020
Triglycerides (mg/dL) 169.4 (7.65) 129.2 (5.04) 151.2 (4.81) <0.001
Glycemia (mg/dL) 110.1 (1.52) 98.9 (0.89) 105.0 (0.94) <0.001
BMI (Kg/m2) 28.9 (0.23) 26.9 (0.27) 27.9 (0.18) <0.001
Blood lead (μg/dL)d 2.04 (1.94-2.15) 1.87 (1.77-1.98) 1.97 (1.89-2.04) 0.029
Occupation (% lead exposed) 11 (0.01) 13 (0.02) 12.0 (0.01) 0.278
aHypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or antihypertensive medication use. bChi-square, Wilcoxon
or Kruskal-Wallis test. cAccording to Associação Brasileira de Empresas de Pesquisa (ABEP, 2012); from 0 (lower income level) to 45 (higher income level). dGeo-
metric mean (95% CI); other results in the table are arithmetic means or percentages (SE)
Almeida Lopes et al. Environmental Health  (2017) 16:27 Page 6 of 10
observed in these associations [3, 29–31]. Bone lead is
considered a long-term biomarker for lead exposure,
representing a cumulative dose in the body, which has
been considered a better assessment of lead in epidemio-
logical studies evaluating associations of cumulative ex-
posures with chronic disease. Blood lead represents a
short-term biomarker, reflecting recent exposure to the
metal, but also provide variability of lead released from
the bones [32]. The mobilization of lead from bone is in-
creased during some periods of life, such as aging, preg-
nancy and after the menopause in women [10, 32, 33].
Studies that measured both bone and blood lead re-
ported that bone lead (patella and tibia bones), was posi-
tively associated with hypertension, while blood lead was
mostly associated with raised blood pressure [34, 35]. So
the associations found between bone lead and current
blood pressure indicate that past exposure as well as
current exposure to lead are important biomarkers to
evaluate blood pressure outcomes.
Studies with general population also found positive as-
sociations between blood lead concentrations and
elevation on both systolic and diastolic blood pressure
[6, 12, 34, 36, 37]. We identified a most significant asso-
ciation of blood lead with diastolic blood pressure
(0.06 mmHg; 95% CI, 0.04–0.09), while other studies re-
ported most significant associations of blood lead with
systolic blood pressure comparing with diastolic blood
pressure [6, 9, 10, 31, 34, 36–38]. This variability is diffi-
cult to be enlightened and may not be restricted to in-
trinsic factors of blood pressure, but also depends on the
measurement technique used, the measurer's ability, and
other conditions under which the measure will be held
[2].
Most recently, Hara et al. [6] reported that blood lead
doubling was associated with higher systolic (+0,76 mm
Hg; 95% CI, 0.38–1.13) and diastolic blood pressure
(+0,43 mm Hg; 95% CI, 0.18–0.68), but not with the odds
of prevalent hypertension in analyzing data from
NHANES 2003–2010. Besides that, the study reported the
results of stratified analysis of blood lead and blood pres-
sure by sex and ethnicity, revealing distinct results regard-
ing each population stratum [6]. Before that, Scinicariello
et al. [39] published data from NHANES 1999–2006 and
reported that blood lead was significantly associated with
higher diastolic blood pressure among white men and
women and in black men, while elevated systolic blood
pressure was associated with blood lead only in blacks,
but not in whites or in Mexican-American participants.
Compared with American population, Brazilian adults
may be exposed to distinct sources of lead, and the influ-
ence of covariates may differ [20]. Besides, although the
present study is based on a representative sample of
adults, the number of participants did not allow us to per-
form a fully stratified analysis.
Unlike what has been observed on the hypertensive ef-
fects of lead in studies involving workers exposed to
high levels of lead, environmental exposure is often
asymptomatic and as other toxic effects of lead, the
magnitude of raised blood pressure depends on the mag-
nitude of the exposure [2, 3, 5, 11, 40, 41]. Another
Table 3 Change (95% CI) of systolic and diastolic blood pressure by blood lead levels (μg/dL)
Systolic blood pressure (mmHg)* Diastolic blood pressure (mmHg)
Model 1 Model 2 Model 1 Model 2
Blood lead (μg/dL)
Quartile 1 (≤1.32) 0.00 (reference) 0.00 (reference) 0.00 (reference) 0.00 (reference)
Quartile 2 (1.32–1.93) −0.00* −0.00* 0.04 (0.01–0.05) 0.03 (0.01–0.05)
Quartile 3 (1.93–2.76) −0.00* −0.00* 0.03 (0.01–0.06) 0.02 (0.00–0.05)
Quartile 4 (>2.76) −0.00* −0.00* 0.07 (0.04–0.09) 0.06 (0.04–0.09)
p-Trend <0.001 0.002 <0.001 <0.001
*All Confidence Intervals (CI) for systolic blood pressure were −0.00 to -.000
Model 1 was adjusted for sex, age (40–49, 50–59, ≥60), race (white, no white), education (years of study), income (continuous; according to Associação Brasileira
de Empresas de Pesquisa, 2012) and antihypertensive medication (yes, no)
Model 2 was further adjusted for continuous total cholesterol (μg/dL), triglycerides (μg/dL), glycemia (μg/dL), smoking status (never, current and former), alcohol
intake (yes, no) and body mass index, continuous (kg/m2)
Table 4 OR (95% CI) of hypertension by blood lead quartiles
(μg/dL)
Model 1 Model 2
Blood lead (μg/dL)
Quartile 1 (≤1.32) 1.00 (reference) 1.00 (reference)
Quartile 2 (1.32–1.93) 0.22 (0.02–2.97) 0.11 (0.01–1.59)
Quartile 3 (1.93–2.76) 0.58 (0.42–8.22) 0.40 (0.02–6.87)
Quartile 4 (>2.76) 2.28 (1.12–4.66) 2.54 (1.17–5.53)
p-Trend <0.001 0.003
90th – 10th percentile 2.62 (1.40–4.91) 2.77 (1.41–5.46)
Model 1 was adjusted for sex (male, female), age (40–49, 50–59, ≥60), race
(white, no white), education (0–3, 4–7, 8–11 and 12 or more years of study),
income (classes A/B, C, D/E; according to Associação Brasileira de Empresas de
Pesquisa, 2012) and antihypertensive medication (yes, no)
Model 2 was further adjusted for continuous total cholesterol (<200 μg/dL,
≥200 μg/dL), triglycerides (<150 μg/dL, ≥150 μg/dL), glycemia (<100 μg/dL,
≥100 μg/dL), smoking status (never, current and former), alcohol intake (yes,
no) and body mass index, continuous (kg/m2)
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perspective on the health effects of lead-associated in-
creases in blood pressure is to consider the effect of a
unit increase in median BLL on the overall distribution
of blood pressure values in a population and the effect
on number of persons with blood pressure elevations as-
sociated with stroke and other endpoints. This was cal-
culated by Schwartz [42], who reported that a 1 μg/dL
increase in mean population blood lead in US white
males aged 40–59, distributed over the range of blood
pressure values in this population, would increase the
numbers of persons at risk for myocardial infarction by
3200 per year, of strokes by 1300 per year, as well as an
overall increase in clinical hypertension of 635,000 more
cases. Pirkle et al. [43], using the opposite approach,
based on a longitudinal analysis of NHANES II data,
from 1976 to 1980, in which blood lead levels in white
males aged 40 to 59 years decreased by 37%, found that
this decrease resulted in 4.7% and 6.7% decrease in fatal
and nonfatal myocardial infarctions and strokes, respect-
ively [43].
The inclusion of confounding factors in regression
models has been considered very important to control
for residuals in such analysis, especially when examining
small effects as the influence of lead in blood pressure
[10]. The inclusion of inappropriate covariates in regres-
sion models can attenuate associations between lead
levels and the studied outcomes. Still, the absence of cer-
tain variables in the analysis may overestimate the
strength of the association [9, 34, 40]. In this study, we
included in the analysis risk factors for cardiovascular
disease such as smoking, alcohol consumption, sex, age,
socioeconomic and demographic variables and BMI to
account for covariates that are known to be associated
with blood pressure outcomes. Even so, some unmeas-
ured variables not included in the analysis may influence
the association of lead and blood pressure as, for ex-
ample, pre-existing diseases, genetic aspects and renal
function [40].
Although not completely elucidated, some mecha-
nisms of lead-related hypertension have been reported,
such as: impaired renal function, reduction of nitric
oxide (NO) bioavailability, increased oxidative stress, in-
creased activity of the renin angiotensin system and
down-regulation of soluble guanylate cyclase. As a con-
sequence of such mechanisms, lead exposure leads to in-
creased vascular tone and induce alterations of the
adrenergic system leading to peripheral vascular resist-
ance [3, 44, 45].
Oxidative stress has been described as the main mech-
anism of lead-induced toxicity. Lead exposure promotes
oxidative stress by enhancing the production of reactive
oxygen species, and by decreasing antioxidant enzymes
activity [45–49]. Even at low levels, lead triggers the oc-
currence of events that are involved with the
development of hypertension and other cardiovascular
diseases, which have been consistently reported in stud-
ies conducted with animals and humans [50, 51]. The
overload of oxygen reactive species leads to tissue injury
and dysfunction through direct interaction with cell
molecules, and through depletion of the antioxidant sys-
tem. Lead interaction with biological macromolecules,
such as lipids, proteins and DNA, results in disturbances
in cell membranes, changing its structure and function-
ing. Beyond that, lead interferes with the activity of im-
portant antioxidant enzymes, such as glutathione, which
can interact directly with reactive oxygen species, or can
serve as a cofactor for the detoxification reactions in the
presence of free radicals [52–55]. The activation of
redox-sensitive transcription factors, such as the nuclear
factor-κB (NF-κB), which stimulates the production of
inflammatory substances associated with renal interstitial
inflammation, and changes in the calcium channels
function leading to alterations in vascular tone and re-
activity, are also important factors contributing for alter-
ations in blood pressure outcomes [51, 56].
Furthermore, lead-induced oxidative stress reduces the
availability of NO, which is an endogenous catalyst of
several biochemical processes with an important role in
cardiovascular system regulation, leading to endothelial
dysfunction [41]. Barbosa Jr et al. [57] reported that lead
exposure exerted a significant inhibitory effect on NO
production, as shown by analyses of nitrite concentra-
tions in adults living in the Southeast region of Brazil,
suggesting that this biological mechanism is possibly re-
lated to the increased cardiovascular risk associated with
lead exposure.
Some positive points to be highlighted in our study are
the census based and the spatial analysis used to enroll
participants. Besides that, the study included the measure-
ment of multiple anthropometric and socioeconomic
characteristics and the standardization of blood pressure
measurements (≥3 readings) based on Brazilian Guide-
lines, taken by trained researchers. However, some limita-
tions of this study are the cross-sectional design that does
not allow causal inferences about the association of blood
lead and blood pressure; and the fact that we may not
have measured all the potential confounders of the rela-
tionship between hypertension and lead exposure.
Finally, we found that participants in the highest quar-
tile of blood lead had an OR for hypertension of 2.54
(95% CI, 1.17–5.53), compared with those in the lowest
quartile, as well as participants in the 90th percentile of
blood lead presented higher OR for hypertension than
those in 10th percentile. Differences observed among
the results of other studies may be related to methodo-
logical issues, as bone lead measurement as a marker of
lead exposure compared with blood lead and to stratified
statistical analysis, which have shown that distinct risk
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factors for lead exposure exist among these populations.
Although education and income have been considered
significant predictors of blood lead levels in Americans,
the historically difference observed among income level
has been decreasing. Furthermore, some Pb-related out-
comes, including blood pressure outcomes, may vary by
race/ethnicity, providing some evidence that some
groups may be at higher risk of developing some dis-
eases [7, 44, 58]. In Brazil these characteristics may have
specific associations with both blood lead levels and
hypertension, indicating that more studies with Brazilian
adults are necessary to evaluate Pb-related health out-
comes, as well as to provide an evaluation of blood lead
levels in the general population.
Conclusions
We found a positive association between blood lead and
diastolic blood pressure, and a significant association of
blood lead and hypertension in Brazilians aged 40 years or
older, living in southern Brazil. Our results add knowledge
about the health risks associated with current environ-
mental exposures to lead in Brazil, and encourage efforts
to prevent lead exposure in the general population.
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